Bristol-Myers Squibb Company today announced new 4-year results from the long-term extensions of the BENEFIT and BENEFIT-EXT clinical trials of NULOJIX® , the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejectio…
ViroPharma Incorporated today announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients.
ViroPharma announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections in transplant recipients. The planned program will consist of two independent …
EXTON, Pa., June 4, 2012 /PRNewswire/ — ViroPharma Incorporated (NASDAQ: VPHM) today announced the initiation of a Phase 2 program to evaluate maribavir for the treatment of cytomegalovirus infections …
PEMBROKE — A Pembroke man who 21 years ago received a new heart and lungs is hospitalized with end-stage kidney failure and needs a life-saving transplant. Paul Harris, 47, was hospitalized Wedn…
CARRYING the Olympic Torch in July will not only be an honour for Whitfield gas engineer Phillip Mallery – it will also be…
CARRYING the Olympic Torch in July will not only be an honour for Whitfield gas engineer Phillip Mallery – it will also be…
Alnylam Pharmaceuticals, Inc.(Nasdaq: ALNY), a leading RNAi therapeutics company, announced today top-line results from a Phase IIb trial with ALN-RSV01 for the treatment of respiratory syncytial virus (RSV) infection in lung transplant patients.
Alnylam Pharmaceuticals Inc. (Nasdaq: ALNY) of Cambridge said today that it missed its goal but saw a “statistically significant reduction” in the incidence of a life-threatening lung disease in lung transplant patients with respiratory syncytial v…
AFTER losing every one of her limbs from a flesh-eating infection, a 43-year-old Texas mother of three will have another person's arms and hands attached to her in the first ever transplant of its kind in the US.